425 - Tempus AI, Inc. (0001717115) (Filed by)

425 - Tempus AI, Inc. (0001717115) (Filed by)

425 - Tempus AI, Inc. (0001717115) (Filed by)

425 - Tempus AI, Inc. (0001717115) (Filed by)

8-K - Tempus AI, Inc. (0001717115) (Filer)

425 - Tempus AI, Inc. (0001717115) (Subject)

8-K - Tempus AI, Inc. (0001717115) (Filer)

144 - Tempus AI, Inc. (0001717115) (Subject)

144 - Tempus AI, Inc. (0001717115) (Subject)

8-K - Tempus AI, Inc. (0001717115) (Filer)

4 - Tempus AI, Inc. (0001717115) (Reporting)

4 - Tempus AI, Inc. (0001717115) (Reporting)

Wolfe Research resumed coverage of Tempus AI with a rating of Peer Perform

Jefferies initiated coverage of Tempus AI with a rating of Underperform and set a new price target of $35.00

TD Cowen upgraded Tempus AI from Hold to Buy and set a new price target of $65.00

Mizuho initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $100.00

Robert W. Baird initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $59.00

Morgan Stanley resumed coverage of Tempus AI with a rating of Overweight and set a new price target of $85.00

TD Cowen downgraded Tempus AI from Buy to Hold and set a new price target of $88.00

Canaccord Genuity initiated coverage of Tempus AI with a rating of Buy and set a new price target of $110.00

H.C. Wainwright initiated coverage of Tempus AI with a rating of Buy and set a new price target of $90.00

BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

4 - Tempus AI, Inc. (0001717115) (Issuer)

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the cancer care continuum and accelerates access to industry-leading technology within the rapidly emerging MRD market, a $20 billion opportunity Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ:PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ab

Findings from the multi-center Articulate Pro study show Paige Prostate improves diagnostic consistency, accelerates turnaround times, and reduces laboratory workloads Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting. The study was a real-world evaluation of the Paige Prostate Suite, an integral part of the Tempus intelligent diagnostics ecosystem, and its integration into routine clinical workflows. AI-assisted review supported pathologists in re-assessing and updating the initial

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the "Events" section of the Tempus Investor Relations website or by clicking here. Alternatively, the call can be accessed via the following: Conference ID: 9053038 United Sta

Issued on behalf of Ventripoint Diagnostics Ltd.As the number of people living with congenital heart disease climbs and most patients in poorer regions go without timely care, a Toronto-based AI imaging company is joining a new global alliance built to close that gap.TORONTO, ON, June 16, 2026 /CNW/ -- Equity Insider News Commentary — Congenital heart disease is the most common birth defect in the world, and the population living with it is growing, not shrinking. According to the World Heart Federation's World Heart Report 2026, congenital heart disease now affects roughly 2% of live births globally, and the number of people living with the condition has climbed to an estimated 16 million w

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled "Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Flutter," was recently published in Heart Rhythm. AF is the most prevalent cardiac arrhythmia and is associated with an increased risk of stroke, heart failure and death. Because AF is frequently asymptomatic and paroxysmal, it

Research highlights how ExomeReveal RNA analysis resolves ambiguity around uncertain variants to enable more genetic disease diagnoses Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM), announced peer-reviewed research demonstrating the potential for variant-specific RNA testing to provide greater clarity for patients who receive a variant of uncertain significance (VUS) result from exome testing. The study, published in Genetics in Medicine Open, showcases how targeted RNA analysis using Ambry's ExomeReveal workflow; an innovative multiomics exome sequencing approach can help resolve uncertain findings and improve diagnost

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00 p.m. ET on Monday, June 8. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of a digital pathology IMS Open-Source Consortium ("IMS Consortium"). Designed to accelerate the democratization and standardization of digital pathology, the consortium aims to bring together leading academic medical centers and industry partners to develop a best-in-class open-source digital pathology platform and viewer. YNHH and MSK are founding academic members of the consortium. As pioneering institutions, they will contribute to defining the vision, governance, and stra

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a whole-genome sequencing (WGS) approach for the detection of actionable oncologic targets in peripheral blood and bone marrow samples from patients with hematologic malignancies. Tempus first announced the xH assay for research use only in January 2025. The test was developed for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and overlap syndromes (MDS/MPN). It is optimized for myeloid neoplasms and is designed to su

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus' multimodal data, AI tooling and computational infrastructure to deliver actionable insights at the pace required for drug development. The next-generation of the Lens platform is built on over a decade of longitudinal real-world data and years of expertise translating that data into actionable evidence for biopharma. Lens combines one of the world's largest real-world multimodal datasets, high-

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of a digital pathology IMS Open-Source Consortium ("IMS Consortium"). Designed to accelerate the democratization and standardization of digital pathology, the consortium aims to bring together leading academic medical centers and industry partners to develop a best-in-class open-source digital pathology platform and viewer. YNHH and MSK are founding academic members of the consortium. As pioneering institutions, they will contribute to defining the vision, governance, and stra

Oran Muduroglu, proven medical imaging entrepreneur, to lead U.S. launch of eyonis® LCS Established U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway already in place to support expansion Active discussions underway to establish key clinical partnerships to support broad access across U.S. lung cancer screening programs Webcasts will be held on February 26, 2026, to discuss the Company's recent achievements and upcoming milestones for eyonis® LCS deployment in the U.S. Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218440005/en/Oran Muduroglu Appointed Presi

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland. "We're excited to join the oncology community at this year's meeting and highlight our latest research and progress in advancing the immuno-oncology field," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Our latest findings demonstrate the potential of integrated, data-driven approaches to refine biomarkers, im

Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the cancer care continuum and accelerates access to industry-leading technology within the rapidly emerging MRD market, a $20 billion opportunity Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ:PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ab

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the "Events" section of the Tempus Investor Relations website or by clicking here. Alternatively, the call can be accessed via the following: Conference ID: 9053038 United Sta

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2026. Revenue of $348.1 million, up 36.1% year-over-year Diagnostics revenue of $261.1 million, representing 34.7% growth year-over-year, driven by Oncology volume growth of 28% MRD volume was ~6,500 tests in Q1 2026, up ~500% year-over-year Data and Applications revenue of $87.0 million, representing 40.5% year-over-year growth, with Insights (data licensing and modeling) growing 44.1% $643.8 million in cash and marketable securities as of March 31, 2026 Increasing revenue guidan

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first quarter ended March 31, 2026 on Tuesday, May 5, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the "Events" section of the Tempus Investor Relations website. For those unable to listen to the live broadcast, a recording will be available on the website following the call. Alt

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4652845 United States - New York: (646) 307-1963 USA & Canada - Toll-Free: (800) 715-9871 Live Webcast: https://edge.media-

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the earnings conference call at 4:30 pm ET. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 5436492 USA & Canada: Toll-Free (800) 715-9871 United States: Toll (646) 307-1963 Live Webcast: https://edge.media-server.com/mmc/p/vg3azega A

Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307

SC 13G - Tempus AI, Inc. (0001717115) (Subject)

SC 13G - Tempus AI, Inc. (0001717115) (Subject)

SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

SC 13G - Tempus AI, Inc. (0001717115) (Subject)

SC 13D - Tempus AI, Inc. (0001717115) (Filed by)